Role of interferon and interferon plus ribavirin in the management of chronic hepatitis C

Journal of the College of Physicians and Surgeons Pakistan

Volumn 12, Issue 10, 2002, Pages 609-612

  Shaikh, Wazir Muhammad ^a   Shaikh, Majid Ahmed ^a   Solangi, G A ^a   Zuberi, B F ^a  

^a Chandka Medical College Hospital Shaheed Muhtarma Benazir Bhutto Medical University Larkana   (Pakistan)

Author keywords

Chronic hepatitis C; Interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHESIS; LEUKOPENIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYALGIA; PAKISTAN; PROSPECTIVE STUDY; PRURITUS; RASH; RELAPSE; REMISSION; SCORING SYSTEM; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

EID: 0036819393     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26: (3 suppl I) : 62S-65S.
2. Arista-Nasr J, Pichardo-Bahena R, Castaneda B, Lisker M, Keirns C. Hepatitis C: a disease with a wide morphological spectrum? J Clin Gastroenterol 1996;22: 121-5.
3. Mattson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A and non B hepatitis, a 13-year follow-up study of hepatitis C virus marker. Liver 1993; 13: 274-8.
4. Naoumov NV, Chokshi S, Metivier E, Maertens G, Johnson PJ, Williams R. Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. J Hepatol 1997;27;331-6
5. Terrault NA, Wright TI. Hepatitis C virus in the setting of transplantation. Semin Liver Dis 1995;115 : 92-100.
6. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, di Bisceglie A, Peters M, et al. Treatment of chronic non-A non-B hepatitis with recombinant-human alpha interferon: a prelininany report. N Engl J Med 1986,315:1575-8.
7. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Parrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-6.
8. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta analysis of interferon randomized trials in the treatment of viral hepatitis C; effects of dose and duration. Hepatolgy 1996;24:778-89.
9. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the longterm treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995 ; 332:1457-62.
10. Lin R, Roach E, Zimmerman M, Strasser S, Fanell GC. Interferon alfa-2b for chronic hepatitis C : effects of dose increment and duration of treatment on response rates. Results of the first multicenter J Hepatol 1995; 23: 487-96.
11. Manesis EK, Papaioannou C, Gioustozi A, Kafiri G, Koskinas J, Hadgiyanni SJ. et al. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6-12 months: a 4-year follow-up of 211 patients. Hepatology 1997;26:734-9.
12. Carithers RL Jr, Emerson SS. Therapy of hepatitis C : meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26: (3 suppl): 83S-8S.
13. Davis GL. Interferon therapy of chronic hepatitis C: update 1995, In : Arroyo V, Bosch J, Rodes J, (edi). Treatment in hepatology. Barcelona: Masson SA, 1995:155-60.
14. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-54.
15. Fernandez H, Banks G, Smith R. Ribavirin : a clinical overview. Eur J Epidemiol 1986; 2: 1-14.
16. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo controlled study. J Hepatol 1996; 25 : 591-8.
17. Poynard T, Marcelpin P, Lee SS, Niederau C, Minuk GS, Ideo G. Randomized trial of interferon alpha 2 b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
18. Knodel RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1: 431-5.
19. The National Institutes of Health Consensus Development Conference. Panel statement: management of hepatitis C. Hepatology 1997; 26 (3 suppl): 2S-10S.
20. Mc Hutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
21. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double blind, placebo controlled trial. Ann Int Med 1995;123: 897-903.
22. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Schiff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473-7.
23. Lindsay KL. Therapy of chronic hepatitis C : overview. Hepatology 1997; 26 (3 suppl): 71S-77S.
24. Tine F, Margin S, Craxi A, Pagliaoro L. Interferon for non A, non-B chronic hepatitis : A meta-analysis of randomised clinical trials. J Hepatol 1991;13 : 192-9.
25. Shindo M, Araii K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of long term response to interferon -alfa therapy. Ann Intern Med 1995;122: 586-91.
26. Brouwer JT, Nevens F, Michielsen P. et al. What options are left when hepatitis C does not responding to interferon ? Placebo-controlled Benelux multicenter retreatment trial on ribavirin monotherapy versus combination with interferon. J Hepatol 1994; 21 ( suppl 1 ) : S17.
27. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 507-12.
28. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of alfa interferon and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23 ( suppl 2):88-12.
29. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12.
30. Interferon relapser and non-responders; Scandivnavian experience. In: Weiland O, Schvarez R, Yun Z, Sonnberg A. perspectives on a new Paradigm: combination anti viral therapy in chronic hepatitis C, London: European Association for the Study of Liver 1995, 441-50.
31. Davis GL, Estebaln Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa -2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Therapy Group. N Engl J Med 1998; 339: 1493-9.
32. Min AD, Jones L, Eposito S, Lebovics E, Jacobson IM, Klion FM, et al. Efficacy of high dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Am J Gasroenterol 2001; 96: 1143-9.
33. Shafi MS, Ahmad SI, Rehan M. Mustafa G. Daily interferon versus interferon thrice weekly in combination with ribavirin for treatment of chronic hepatitis C. JRMC 1999;31: 20-2.
34. Peters M. Actions of cytokines on the immune response and viral interactions; an overview. Hepatology 1996; 23: 909-16.
35. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human to cells in culture. Hepatology 1995; 21: 1003-10.